Source: Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Christopher H. Goss, Isabelle Fajac, Raksha Jain, Wolfgang Seibold, Abhya Gupta, Ming-Chi Hsu, Sivagurunathan Sutharsan, Jane C. Davies, Marcus A. Mall. Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study. Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021

Member's Comments

No comment yet.

Related content which might interest you: An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1 Source: ERJ Open Res, 6 (4) 00395-2020; 10.1183/23120541.00395-2020 Year: 2020 Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Late Breaking Abstract - Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Safety and efficacy of inhaled human α-1 antitrypsin (AAT) in cystic fibrosis: a report of a phase II clinical study Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009 A randomized, placebo controlled 4-week study in COPD of QBW251, a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 LATE-BREAKING ABSTRACT: Randomised, double blind, placebo-controlled phase III study of inhaled dry powder mannitol in cystic fibrosis (CF) Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009 Nasal high-flow therapy (NHFT) during exercise in patients with cystic fibrosis (CF): a randomized crossover trial Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007 Design of phase II, randomized, placebo-controlled study of loratadine associate with rapamycin in patients with lymphangioleiomyomatosis (LAM) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019 Late Breaking Abstract: A randomised, placebo controlled trial of 6 weeks‘ treatment with a novel oral p38 inhibitor in patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018